Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis.

Che H, Lukas C, Morel J, Combe B.

Joint Bone Spine. 2014 May;81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7. Review.

PMID:
23932722
2.

Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.

Segan J, Staples MP, March L, Lassere M, Chakravarty EF, Buchbinder R.

Intern Med J. 2015 Mar;45(3):310-8. doi: 10.1111/imj.12679.

PMID:
25565419
3.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

4.

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.

Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1671-8. doi: 10.1002/acr.22628.

5.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Epub 2014 Jan 8. Review.

PMID:
24401994
6.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
7.
8.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

9.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
10.

Psoriatic arthritis treatment and the risk of herpes zoster.

Zisman D, Bitterman H, Shalom G, Feldhamer I, Comanesther D, Batat E, Greenberg-Dotan S, Cohen S, Cohen AD.

Ann Rheum Dis. 2016 Jan;75(1):131-5. doi: 10.1136/annrheumdis-2013-205148. Epub 2014 Sep 26.

PMID:
25261573
11.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
12.

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.

Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL.

Ann Rheum Dis. 2016 Oct;75(10):1843-7. doi: 10.1136/annrheumdis-2016-209131. Epub 2016 Apr 25.

13.

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials.

Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L.

Ann Rheum Dis. 2010 Oct;69(10):1756-61. doi: 10.1136/ard.2008.098822. Epub 2009 Jul 28. Review. Erratum in: Ann Rheum Dis. 2012 Aug;71(8):1434.

PMID:
19640854
14.

Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.

Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, D'Amelio R.

J Transl Med. 2014 Mar 22;12:77. doi: 10.1186/1479-5876-12-77.

15.

Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.

Wolfe F, Michaud K, Chakravarty EF.

Rheumatology (Oxford). 2006 Nov;45(11):1370-5. Epub 2006 Sep 26.

PMID:
17003175
16.

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.

Lee YH, Bae SC, Song GG.

Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154. Review.

PMID:
24164839
17.

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.

PMID:
24338344
18.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
19.

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M.

PLoS One. 2012;7(11):e48991. doi: 10.1371/journal.pone.0048991. Epub 2012 Nov 14.

20.

Performance of the 2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta-analysis.

Sakellariou G, Scirè CA, Zambon A, Caporali R, Montecucco C.

PLoS One. 2013;8(2):e56528. doi: 10.1371/journal.pone.0056528. Epub 2013 Feb 20.

Supplemental Content

Support Center